AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study

Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases

NCT06870253 ·Status: ACTIVE_NOT_RECRUITING

Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder

NCT06289283 ·Status: ACTIVE_NOT_RECRUITING

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461 ·Status: COMPLETED ·Phase: PHASE2

Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder

NCT02745301 ·Status: COMPLETED

Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

NCT05643690 ·Status: SUSPENDED

Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer

NCT06235853 ·Status: COMPLETED

A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting

NCT02560584 ·Status: COMPLETED ·Phase: PHASE3

Study of bladdeR Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02

NCT06780358 ·Status: ENROLLING_BY_INVITATION ·Phase: NA

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT05483868 ·Status: RECRUITING ·Phase: PHASE1

The Cxbladder Rule-out of Recurrent Urothelial Carcinoma

NCT03673202 ·Status: UNKNOWN

Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics

NCT06373055 ·Status: RECRUITING

UroX Biomarker Bladder Cancer Study

NCT03973307 ·Status: UNKNOWN

Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer

NCT04726735 ·Status: COMPLETED

Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710

NCT02756637 ·Status: COMPLETED

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

NCT06020807 ·Status: COMPLETED

Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool

NCT06878027 ·Status: RECRUITING

Bladder Cancer Patient-Reported Outcomes

NCT01090388 ·Status: COMPLETED

Evaluation of a Patient-Reported Symptom Index for NMIBC

NCT03091764 ·Status: COMPLETED

Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic

NCT04770974 ·Status: UNKNOWN

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

NCT02968732 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

To Detect the Sensitivity of the UroMark Assay

NCT02781428 ·Status: COMPLETED

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

NCT06350734 ·Status: ACTIVE_NOT_RECRUITING

Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB)

NCT07029256 ·Status: RECRUITING

Drug Screening Using IMD in Bladder Cancer

NCT06204614 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1